Aptar Pharma discusses bioequivalence testing for inhaled generics

Aptar Pharma is featured in the November 2019 edition of ONdrugDelivery magazine, which focuses on Pulmonary & Nasal Drug Delivery.

In this interesting article entitled “A Faster, More Cost-Effective Alternative to Generic Bioequivalence”, Dr. Jag Shur, CEO of Nanopharm, an Aptar Pharma company, explores the challenges companies face in bringing generic respiratory and nasal therapies to market amidst a changing regulatory landscape.  He explains the Aptar Pharma Services range for accelerating and derisking OINDP development, and introduces the CPhI 2019 Award winning SmartTrack^™ as an alternative to bioequivalence studies.

Aptar Phar,a discusses bioequivalence testing for inhaled generics bioequivalence testing for inhaled generics.